CIK 0001159036 · Large accelerated filer
HALOZYME THERAPEUTICS, INC.
Sign in to watch- Ticker
- HALO
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 880488686
- Phone
- (858) 794-8889
- Business address
- 12390 EL CAMINO REAL, SAN DIEGO, CA, 92130
- Former names
- HALOZYME THERAPEUTICS INC, GLOBAL YACHT SERVICES INC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $19,884,955
- in 5 filings, $19.9M under 10b5-1 plans
Net −$19,884,955. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-10-08 | Torley Helen PRESIDENT AND CEO | Option exercise 10b5-1 | +20,000 | $18.41 | $368K | 787,780 |
| 2026-10-08 | Torley Helen PRESIDENT AND CEO | Sale 10b5-1 | −4,810 | $108.18 | $520K | 782,970 |
| 2026-10-08 | Torley Helen PRESIDENT AND CEO | Sale 10b5-1 | −3,090 | $108.91 | $337K | 779,880 |
| 2026-10-08 | Torley Helen PRESIDENT AND CEO | Sale 10b5-1 | −11,900 | $110.00 | $1.3M | 767,980 |
| 2026-10-08 | Torley Helen PRESIDENT AND CEO | Sale 10b5-1 | −200 | $110.51 | $22K | 767,780 |
| 2026-10-08 | Torley Helen PRESIDENT AND CEO | Option exercise · Option to Purchase Common Stock 10b5-1 | −20,000 | $18.41 | $368K | 21,552 |
| 2026-10-07 | Torley Helen PRESIDENT AND CEO | Option exercise 10b5-1 | +20,000 | $18.41 | $368K | 787,780 |
| 2026-10-07 | Torley Helen PRESIDENT AND CEO | Sale 10b5-1 | −8,600 | $111.03 | $955K | 779,180 |
| 2026-10-07 | Torley Helen PRESIDENT AND CEO | Sale 10b5-1 | −10,300 | $111.84 | $1.2M | 768,880 |
| 2026-10-07 | Torley Helen PRESIDENT AND CEO | Sale 10b5-1 | −900 | $112.78 | $102K | 767,980 |
| 2026-10-07 | Torley Helen PRESIDENT AND CEO | Sale 10b5-1 | −200 | $113.69 | $23K | 767,780 |
| 2026-10-07 | Torley Helen PRESIDENT AND CEO | Option exercise · Option to Purchase Common Stock 10b5-1 | −20,000 | $18.41 | $368K | 41,552 |
| 2026-10-06 | Torley Helen PRESIDENT AND CEO | Option exercise 10b5-1 | +20,000 | $18.41 | $368K | 787,780 |
| 2026-10-06 | Torley Helen PRESIDENT AND CEO | Sale 10b5-1 | −2,300 | $107.90 | $248K | 785,480 |
| 2026-10-06 | Torley Helen PRESIDENT AND CEO | Sale 10b5-1 | −6,000 | $109.33 | $656K | 779,480 |
| 2026-10-06 | Torley Helen PRESIDENT AND CEO | Sale 10b5-1 | −9,920 | $109.89 | $1.1M | 769,560 |
| 2026-10-06 | Torley Helen PRESIDENT AND CEO | Sale 10b5-1 | −1,780 | $110.81 | $197K | 767,780 |
| 2026-10-06 | Torley Helen PRESIDENT AND CEO | Option exercise · Option to Purchase Common Stock 10b5-1 | −20,000 | $18.41 | $368K | 61,552 |
| 2026-10-01 | Daly James M Director | Grant or award | +1,169 | 1,169 | ||
| 2026-10-01 | Daly James M Director | Grant or award · Option to Purchase Common Stock | +1,775 | 1,775 |
Page 1 of 26 · 513 trades